Feedback / Questions
UB-VV111 - AbbVie
https://www.globenewswire.com/news-release/2025/09/30/3158491/0/en/Umoja-Biopharma-Announces-that-UB-VV111-Receives-FDA-Fast-Track-Designation-for-Relapsed-Refractory-B-Cell-Malignancies.html
Sep 30, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next